Cardiff Oncology Inc (CRDF) plunge -1.11% in a week: will this be a lucky break through?

Cardiff Oncology Inc (NASDAQ: CRDF) started the day on Wednesday, with a price decrease of -0.74% at $5.33, before settling in for the price of $5.37 at the close. Taking a more long-term approach, CRDF posted a 52-week range of $0.94-$6.42.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 9.26%. Meanwhile, its Annual Earning per share during the time was 35.42%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -4.78%. This publicly-traded company’s shares outstanding now amounts to $44.68 million, simultaneously with a float of $41.07 million. The organization now has a market capitalization sitting at $238.14 million. At the time of writing, stock’s 50-day Moving Average stood at $3.12, while the 200-day Moving Average is $1.88.

Cardiff Oncology Inc (CRDF) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Cardiff Oncology Inc’s current insider ownership accounts for 8.07%, in contrast to 12.13% institutional ownership. According to the most recent insider trade that took place on Dec 19 ’23, this organization’s Director bought 30,000 shares at the rate of 1.37, making the entire transaction reach 41,100 in total value, affecting insider ownership by 697,761.

Cardiff Oncology Inc (CRDF) Earnings and Revenue Records

In the latest quarterly report released, which was put into the public domain on 12/30/2023, the organization reported -$0.21 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.28) by $0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.

Cardiff Oncology Inc’s EPS decrease for this current 12-month fiscal period is -4.78% and is forecasted to reach -1.05 in the upcoming year.

Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators

Let’s observe the current performance indicators for Cardiff Oncology Inc (CRDF). It’s Quick Ratio in the last reported quarter now stands at 7.41. The Stock has managed to achieve an average true range (ATR) of 0.59. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 486.01.

In the same vein, CRDF’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.93, a figure that is expected to reach -0.25 in the next quarter, and analysts are predicting that it will be -1.05 at the market close of one year from today.

Technical Analysis of Cardiff Oncology Inc (CRDF)

If we take a close look at the recent performances of Cardiff Oncology Inc (NASDAQ: CRDF), its last 5-days Average volume was 0.97 million that shows plunge from its year to date volume of 1.62 million. During the previous 9 days, stock’s Stochastic %D was recorded 44.11% While, its Average True Range was 0.63.

Raw Stochastic average of Cardiff Oncology Inc (CRDF) in the period of the previous 100 days is set at 80.11%, which indicates a major rise in contrast to 50.90% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 99.65% that was lower than 123.38% volatility it exhibited in the past 100-days period.